PURPOSE: Colon cancer overall survival (OS) is usually computed from the time of diagnosis. Survival gives the initial prognosis but does not reflect how prognosis changes with changing hazard rates over time. Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS|OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information. We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]). PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS). RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years. For stage III, OS|DFS improved from 69% to 88%. Patients younger than 50 years showed OS|DFS improvement from 79% to 95%; those older than 70 years showed no sustained increase in OS|DFS. Node-negative patients with > or = 12 nodes resected showed little change (89% to 94%); those with more than four positive nodes showed an improvement (57% to 86%). Patients with a PS of 0 or 1 demonstrated a small improvement; those with a PS of 2 did not (64% to 58%). CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes. OS|DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.
PURPOSE:Colon cancer overall survival (OS) is usually computed from the time of diagnosis. Survival gives the initial prognosis but does not reflect how prognosis changes with changing hazard rates over time. Conditional survival (probability of surviving y additional years given they have survived x years [CS or OS|OS]) is an alternative measure that accounts for elapsed time since diagnosis, providing more relevant prognostic information. We extend the concept of CS to condition on the set of patients alive, recurrence-free, and second primary cancer-free (disease-free survival [OS|DFS]). PATIENTS AND METHODS: Using data from National Surgical Adjuvant Breast and Bowel Project trials C-03 through C-07, 5-year OS|DFS was calculated on patients who were disease free up to 5 years after diagnosis, stratified by age, stage, nodal status, and performance status (PS). RESULTS: For stage II, OS|DFS improved from 87% to 92% at 5 years. For stage III, OS|DFS improved from 69% to 88%. Patients younger than 50 years showed OS|DFS improvement from 79% to 95%; those older than 70 years showed no sustained increase in OS|DFS. Node-negative patients with > or = 12 nodes resected showed little change (89% to 94%); those with more than four positive nodes showed an improvement (57% to 86%). Patients with a PS of 0 or 1 demonstrated a small improvement; those with a PS of 2 did not (64% to 58%). CONCLUSION: Prognosis improves over time for almost all groups of patients with colon cancer, especially those with positive nodes. OS|DFS is a more relevant measure of prognosis for those who have already survived disease free a period of time after diagnosis.
Authors: Samuel J Wang; Rachel Emery; Clifton D Fuller; Jong-Sung Kim; Dean F Sittig; Charles R Thomas Journal: Gastric Cancer Date: 2007-09-26 Impact factor: 7.370
Authors: Barry C Lembersky; H Samuel Wieand; Nicholas J Petrelli; Michael J O'Connell; Linda H Colangelo; Roy E Smith; Thomas E Seay; Jeffrey K Giguere; M Ernest Marshall; Andrew D Jacobs; Lauren K Colman; Atilla Soran; Greg Yothers; Norman Wolmark Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: M L G Janssen-Heijnen; S Houterman; V E P P Lemmens; H Brenner; E W Steyerberg; J W W Coebergh Journal: Ann Oncol Date: 2007-08 Impact factor: 32.976
Authors: Samuel J Wang; Amanda R Wissel; Celine B Ord; Jayashree Kalpathy-Cramer; C David Fuller; John M Holland; Neil D Gross Journal: Otolaryngol Head Neck Surg Date: 2011-07 Impact factor: 3.497
Authors: Lauren C Harshman; Wanling Xie; Georg A Bjarnason; Jennifer J Knox; Mary MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Min-Han Tan; Sun-Young Rha; Frede Donskov; Neeraj Agarwal; Christian Kollmannsberger; Scott North; Brian I Rini; Daniel Y C Heng; Toni K Choueiri Journal: Lancet Oncol Date: 2012-08-08 Impact factor: 41.316
Authors: Y Zhu; Y P Hong; H L Zhang; G H Shi; W J Xiao; Z H Wang; X D Yao; S L Zhang; B Dai; D W Ye Journal: J Cancer Res Clin Oncol Date: 2012-06-29 Impact factor: 4.553
Authors: Samuel J Wang; Amanda R Wissel; Join Y Luh; C David Fuller; Jayashree Kalpathy-Cramer; Charles R Thomas Journal: Ann Surg Oncol Date: 2011-01-05 Impact factor: 5.344
Authors: Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: David Luyimbazi; Rebecca A Nelson; Audrey H Choi; Lily Li; Joseph Chao; Virginia Sun; John B Hamner; Joseph Kim Journal: J Gastrointest Surg Date: 2014-11-25 Impact factor: 3.452